PRODUCT INTRODUCTION
Description
Empagliflozin is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medication for diabetes. It was approved by the FDA in 2014. Engeletin can be used as a single drug or in combination with other anti-diabetic products. Combinations include engeletin and riligotine and engeletin in combination with metformin.
Indications
Empagliflozin is used to treat type 2 diabetes, improve heart failure and chronic kidney disease (CKD).
mechanism of action
Empagliflozin acts by inhibiting sodium-glucose cotransporter-2 (SGLT-2) in the proximal renal tubules of the kidney. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of glucose and increases urinary excretion of glucose. Empagliflozin also reduces sodium and volume loading, inducing intravascular constriction through its diuretic and natriuretic properties. In addition, empagliflozin reduces body weight and lowers blood pressure without increasing heart rate.
side effects
Common side effects of Empagliflozin include: genital infections, urinary tract infections, hypotension, dehydration, hypoglycaemia, dyslipidaemia.